Bellarmine, business incubator partnering to advance women of color bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
The ventilator has been named Jeeva Vayu-50, or JV-50. At a time when reports are rife about a spike in the number of COVID-19 patients needing ventilator support and ICU care, a Kochi-based startup has started commercial production of a cost effective and compact Covid-specific ventilator at the Technology Business Incubator (TBI) of the Kalady-based Adi Shankara Institute of Engineering and Technology.
The ventilator has been named Jeeva Vayu-50, or JV-50.
Having turned its focus to biomedical products during the first wave of the pandemic, the startup, Machbee Innovations Private Limited, has since developed three variants of the ventilator, each a refined version of the previous one. While they had multiple partners in the beginning, the latest redesigned version was developed solely by the startup.
Hyderabad varsity startup develops stem cell-based treatment for Covid
Top Searches:
IANS | Updated: May 4, 2021, 09:46 IST
A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for Covid patients.
Picture used for representational purpose only
HYDERABAD: A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for Covid patients.
Transcell Oncologics has developed a proprietary cell-based platform technology, HEMATO UC-MSCs, with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities.
Significantly improved patient survival and time to recovery observed following the treatment, says Transcell Oncologics
A breakthrough human Umbilical Cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs)-based therapy to COVID patients has been announced by Transcell Oncologics,
a biotech start-up company, incubated at ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH) on Monday.
The firm had developed proprietary cell-based platform technology ‘HEMATO UC-MSCs’ with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities. The research recommends HEMATO UC-MSCs to be administered as “two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart to the COVID patients.